Highlights

• All figures in United States dollars. Program permits issuance of up to $75 million of common shares at prevailing market prices through Jefferies LLC as sales agent.

• Shares will be distributed only on the Nasdaq Capital Market or other United States trading markets, not on the Toronto Stock Exchange.

• Proceeds are intended for CardiolRx in recurrent pericarditis, including a potential New Drug Application, plus CRD-38 and general purposes.

Clinical-stage biotechnology companies live and die by their funding runway, and Cardiol Therapeutics Inc. (TSX:CRDL) used a release on Tuesday of last week to add flexibility to its own. The Toronto-based company, whose shares are also quoted on the Nasdaq, announced an at-the-market Equity offering program that allows it to issue up to seventy-five million dollars in United States currency of common shares through Jefferies LLC as sales agent. Because the announcement preceded the most recent trading session, it is labelled an extended-window item.

How an At-The-Market Program Works

An at-the-market program differs from a traditional underwritten offering. Rather than pricing a large block at once, the company can distribute shares gradually through a sales agent in ordinary brokers' transactions at prevailing market prices. Cardiol retains full discretion over timing and quantity and has no obligation to issue any shares, so actual gross proceeds could fall well below the maximum amount.

In this case, shares will be distributed only on the Nasdaq Capital Market or other United States trading markets. The release states that nothing will be placed on the Toronto Stock Exchange or elsewhere in Canada. The Toronto exchange has conditionally approved the program, and Nasdaq has been notified. The program ends on the earliest of complete issuance, termination under the agreement, or expiry of the Canadian base shelf prospectus.

The Regulatory Paper Trail

Distributions will occur under a prospectus supplement dated November third, which supplements Canadian and United States final base shelf prospectuses dated in mid-September. The United States filing is a registration statement on the multijurisdictional disclosure system form that became effective the following day.

The timeline is instructive. In early September the company filed a preliminary base shelf prospectus for a larger amount after a review by Ontario Securities Commission staff, and within weeks the final shelf was in place. The new program is therefore one of the first practical uses of that shelf.

Pipeline Behind the Funding

Cardiol describes itself as a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead program, CardiolRx, targets recurrent pericarditis, an inflammatory condition of the sac surrounding the heart, while a second candidate is in earlier development. Its website lists pericarditis, myocarditis, heart failure and the inflammasome as areas of focus.

The central clinical milestone is the Phase III MAVERIC trial. In late September, the company reported that it had reached its enrollment target ahead of schedule and expanded the trial. That progress matters because proceeds from the new program are intended, among other things, to support CardiolRx development in recurrent pericarditis, including, subject to the trial outcome, preparation of a New Drug Application. Funds may also support clinical work on the second candidate, general and administrative expenses, Working Capital and other costs.

Capital Formation Pattern

The company has used several financing tools in a short span. In mid-September, Warrant exercises brought in more than seven million dollars, and the preliminary shelf for a larger sum followed days earlier. Layering a flexible at-the-market Facility on top of those steps gives management multiple ways to match capital raised to development milestones and market conditions.

For readers who follow Healthcare Stocks, the trade-off is familiar across biotechnology. Gradual issuance can limit the pricing pressure of a single large transaction, yet repeated use of such a program increases the number of shares outstanding and can dilute existing shareholders. Management's discretion means the actual pace is unknowable until quarterly filings report how much was used.

Cost of Capital and Dilution Considerations

Equity funding is the lifeblood of companies without product revenue, and the cost of that capital is measured in ownership percentage rather than interest. Each share issued under the program reduces the proportional stake of existing shareholders, although proceeds added to the Balance Sheet can extend the period during which the company may fund clinical work without seeking other sources. Investors typically weigh that dilution against the value created by hitting trial milestones sooner.

At-the-market programs also offer a signalling dimension. Some Market Participants read the establishment of a facility as a sign that management wants optionality ahead of a pivotal readout, while others focus on the potential for steady Supply of new shares. The release itself provides no information about intended pace, so neither interpretation can be confirmed from the document.

Pre-revenue developers also face operating costs that continue regardless of trial timing, including clinical site expenses, Manufacturing of study supply, regulatory consulting and public-company compliance. A diversified set of funding tools helps absorb those fixed commitments if a study timeline shifts, which is why the shelf and program together are better viewed as infrastructure than as a one-time raise.

Canadian and Sector Context

Cross-listed Canadian biotechnology firms often rely on United States Capital Markets because the pool of specialist life-science investors is deeper there. The structure here reflects that reality, with issuance directed to Nasdaq while the Toronto listing provides a domestic anchor and Canadian regulatory oversight through the securities commissions. Companies of this type are typically followed more for clinical milestones than for earnings, and share prices can respond sharply to trial news or financing announcements.

Within the [S&P/TSX Composite Index], healthcare carries a small weighting, so developers like Cardiol seldom move benchmark returns. Interest-rate expectations, including decisions from the Bank of Canada and the Federal Reserve, still influence appetite for pre-revenue companies because future cash flows are discounted more heavily when borrowing costs are elevated.

Risks and Milestones to Track

Biotechnology timelines are inherently uncertain and difficult to forecast, and financing announcements are only one input into how a developer progresses.

Risks cited in the release and in the annual information form and Annual Report filed in the spring include those tied to commercialization, clinical studies and the MAVERIC trial itself. A negative or ambiguous trial result would reshape the funding picture, while a positive result could improve access to capital on better terms. Regulatory review timelines for any application are also uncertain.

Items worth monitoring include the pace of use of the new program as disclosed in future filings, topline timing for MAVERIC, progress on the second candidate, the cash position reported in the next quarterly results, and any further shelf filings. Together, these will show whether the program serves as a bridge to a pivotal readout or an early step in a longer series of raises.